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Abstract: The use of hormonal contraception is commonly associated with weight gain. The purpose of this retrospective study was
to explore the association between the use of hormonal contraception and weight change in an outpatient adolescent patient
population in Lexington, Kentucky. Data were gathered from the charts of 259 adolescent female patients seen in an outpatient
adolescent clinic for up to 72 months. At the initial visit, all patients were evaluated for risk-taking behavior and received preventive
counseling. Patients were categorized as either contraception users or non-users (control group). Contraception users were subdivided
into Depot Medroxyprogcstcronc Acetate (DMPA) user group or non-DMPA contraception user group. The latter group included
patients using oral contraceptive pills, transdermal contraceptive patch, intravaginal. contraceptive ring, or other forms of hormonal
contraception. Following the initial visit, all contraception users (DMPA and non-DMPA) visited the clinic every three- or sixmonths for follow-up. During the follow-up visits, patient weight was recorded and the patient received counseling services by a
physician, a licensed psychologist, and/or a nutritionist as deemed appropriate. Data were entered in Microsoft Excel and analyzed
using Statistical Analysis Software. The results showed no significant difference in weight gain between groups. We hypothesize that
hormonal contraception in adolescent patients, coupled with clinical intervention in form of counseling and regular monitoring, over
an extended period (longer than 24 months) is not associated with significant weight gain.
Keywords: Adolescent, contraception, clinical counseling, DMPA
Correspondence: Professor Hatim A Omar, MD, FAAP, Director of Adolescent Medicine and Young Parent programs, 1422
Kentucky Clinic, Dept. of Pediatrics, Kentucky Ch ildren's Hospital, University of Kentucky College of Medicine, Lexington, KY
40536 USA. Tel: 859-323-6426 ext. 31 1; Fax. 859-257-7706; E-mail : haomar2@uky.edu
Submitted: December 15, 2008. Revised: January 20, 2009. Accepted: January 30, 2009.

INTRODUCTION

In its most recent release, the American Academy of
Pediatrics Policy on Contraception and Adolescents
continues to recommend prOVISion of hormonal
contraception to adolescents by their primary care
physicians (1 ,2). Hormonal contraception is available in
various forms including combined oral contraceptive
pills, injections, skin patches, subcutaneous implants,
and vaginal rings (3). Oral contraceptive pills (OCPs)
are the most popular method among adolescents and
their protective, therapeutic, and non-contraceptive uses
in gynecologic diseases are well documented (2,4-6).
Depot Medroxyprogesterone Acetate (DMPA) is the
major injectable contraceptive in the United States ( 4).
DMPA injections, similar to OCPs, offer safe, effective,
convenient, and reversible birth control choices (7).
DMPA injection use is also favorable to use in
adolescents who have low compliance rates with OCPs

(8) and are gaining appeal among adolescents, because
of their effectiveness (9).
Despite the proven benefits of hormonal contraceptives, a number of controversies have emerged due
to their side effects. The OCPs are commonly associated
with cardiovascular complications, breakthrough
bleeding, and migraine headaches (2-4, 10). Injectable
contraceptives, on the other hand, are commonly
associated with vaginal bleeding ( 11, J2), decreased
bone mineral density, and abdominal pain (1 3). Both
oral and injectable contraceptives have been associated
with weight gain (3-5, 10,1 I, 13-16).
Numerous retrospective and prospective clinical
studies conducted in the U nited States explored the
relation between hormonal contraception and weight
gain. A 24 month study by Berenson et at ( II) of 16-33
year old females found that the odds of weight gain for
patients using OCPs or DMPA after 24 months were
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1.19 and 2.27, respectively, compared with the control
group odds of l.OO. In another 12 month study,
adolescent Norplant implant users gained more weight
than oral contraceptive users (8.7 vs. 4.2 pounds
respectively) (17). As for DMPA usc, a 30-month
prospective experimental study of low socioeconomic
status adolescent African American patients, weight
gain was the most commonly perceived side effect and
the primary reason for discontinuation of treatment (18).
The finding of weight gain seems to be universal;
Austrian high school adolescents who started using the
pill at a mean age of 16.0 ± 0.9 years noted weight gain
as a s ide effect in addition to an increase in breast size,
fatigue, and depression ( 19).
Contrary to the findings above, other studies showed
no significant change in weight with the use of
hormonal contraception. A randomized, parallel-group,
multicenter study showed that use of OCPs does not
substantially affect body weight for most women after
13 cycles of use (20). A study of adolescent and young
women using oral contraceptive pills or intra-uterine
devices (fUD) as a control group, showed no significant
difference between the OCP and IUD groups in initial
weight and weight after one year of use (21 ). A more
recent study comparing OCP use to a placebo-controlled
group in adolescent subjects showed that changes in
body weight and the incidence of estrogen-related side
effects in the OCP group after six cycles were not
significantly different from placebo-controlled group
(22). Due to the numerous controversies in the literature
regarding weight gain due to the use of contraceptives,
we aim to determine once and for all the effects of
contraceptives on weight gain. To this end, we used the
patient charts of patients who were on different oral
contraceptive use for at least one year, as well as a
'contro!' group who are not using contraceptives.
METHODS
Data were gathered from the charts of 313 adolescent
female patients seen in an outpatient adolescent clinic in
Lexington, Kentucky. At the initial visit, all patients were
evaluated for risk-taking behavior using the Perkins'
Adolescent Risk Screen (PAR.S) form (I). PAR.S is a
validated screen that assesses a variety of health-related
variables, such as Body Mass Index (BMl), nutrition,
drug use, and sexual activity, in addition to other
biopsychosocial factors (23). Following this assessment,
all patients received preventive counseling by a certified
psychologist in the clinic.
Hormonal contraception including Depot Medroxyprogesterone Acetate (DMPA) method or non-DMPA

methods (including oral contraceptive pill, patch, ring or
other forms) was prescribed to a subset of these patients
following consultation with the attending physician and
the patient. Follow-up visits were scheduled every three
months for DMPA contraception users and every 3-6
months for non-DMPA contraception users. During
follow-up visits, patient weight was recorded and other
screening tests such as HPV (human papillomavirus)
screening were conducted. In addition, every patient
received counseling by a team composed of a
psychologist, social worker, nutritionist, and a nurse
practitioner. Data collected from patient charts included
demographic information, weight data, HPV screen
results, risk taking behavior, and pertinent medical
conditions.
Data were entered and BMT was calculated in
Microsoft Excel. Data were entered as "missing value"
for patients who discontinued hormonal contraception
or discontinued visiting the clinic. Statistical Analysis
Software (1) was used to analyze the data coded in
Excel. The dem ographic data were analyzed using
descriptive statistical measures. A one-way ANOVA
statistical test was performed to compare weight change
and BMI change in the hormonal contraception user
group vs. the control group at the initial v isit and every
year thereafter. The same analysis was conducted to
compare the DMPA vs. non-DMPA groups. The two
groups were compared at the end of years I , 2, 3, 4, 5,
and 6 using ANOVA Scheffe's method P < .05 was
considered statistically significant.
Exclusion criteria: patients who used contraception
for less than one year or switched contraception
methods in less than one year were also excluded. Using
these criteria, the final number of patients in the study
was 259.
RESULTS
The age range of the patients included in the study was
12-21 years at the beginning of the study. The mean age
was 18.1 ± 2.4 years. The median value for age was
16.5 years and the mode value was 19.5 years. Of the
patients, 98% reported their status as s ingle, 2% as
married or engaged. In terms of racial distribution, 49%
of the patients were Caucasian, 50% African American,
and I% Hispanic. Insurance type was used as an index
of socioeconomic status. The vast majodty of patients
(72%) were Medicaid recipients, whereas 21 % were
private insurance carriers. The remaining 7% of patients
had no insurance plan and were recipients of fmancial
assistance. With respect to smoking status, most patients
(66%) were non-smokers whereas 34% were smokers.

WEIGHT GAIN AND ADOLESCENTS

Table I: Demographic characteristics ofsubjects at the
beginning of the study (n =313)
Age
Age Range
Marital Status

Race

Insurance Status
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Smoking Status*
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Contraception group

Mean±S.D.
15.8±2.2

Median
16.0

Minimum

Maximum

8.5

21.0

Single

Mode
16.0

None

Medicaid

22.4%

6.3%

71.3%

30.6%

69.4%

Yes

No

25.1%

74.9%

User

Non-User

25

c:

8.

..g>
..

.E

~

Private

No

30

::1

20
15
10
5
0

Cll

47.9%

Yes

..
u

Other

Caucasian

'C

.&:

1.8%
African
American
47.2%

97.2%

40

:0
:::;. 35

l:

Married
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-5
-10

Year

• Birth control user group
0 non-user group

4.9%

215
98
Subjects pe group (n)
*Other includes Hispanic, Native American, Oriental, and biracial
patients.
**The smoking status data not available for 15% of the patients.
••• Substance abuse data not available for 30% of the patients.

Year
Graph 1: Weight change in
pounds per year in contraception
user and control groups.

1

2
3
4
5
6

N per group
Users Controls
214
42
136
22
76
10
38
4
16
3
9
2
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25
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!
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15
10

5
0

2

4

3

5

6

Year

However, the smoking slatus was missing for 15% of all
subjects in the study. Regarding substance abuse, 26%
of patients admitted abusing alcohol, drugs, or both ,
whereas 74% of patients denied abusing either alcohol
or drugs (see table 1).
As previously mentioned, patient weight (in pounds)
was recorded at the initial and each follow-up visit.
Weight changes per patient were calculated at the end of
each year for patients in the contraception user and nonuser (control) groups. A significanl difference in the
weight changes between the two groups was seen at the
end of year I (p = .03). In contrast, no significant
differences were observed in the following years (see
graph 1).
Subsequently, the BMl calculation was used to
compar:: patients in the contraception user and control
groups as described above. No significant difference
was found between the two groups at any time point,
including year I (see graph 2). The height variable was

• Birth control user group
0 non-user group

Graph 2: Body Mass lndex (BMl)
change per year in both contracepbon user and control groups.

Year
1
2
3
4
5
6

N per group
Users Controls
96
34
53
12
33
6
15
3
6
3
2
2

not documented for all patients, therefore accounting for
decrease in then value of patients in this graph.
DISCUSSION
As mentioned previously, the literalure is abundant with

conflicting results on the association of hormonal
contraception with weight change in adolescents (I I, 13-
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19,22). The disparity between these results could be due
to a number of factors. First, the duration of most
studies reported to date is relatively short. Most studies
did di not extend past 24 months (II), 13 cycles of use
(20), one year of use (17,21,24) or six cycles of use
(22). Only one study tracked patients for a duration of
30 mor!hs. This study, however, had a significant dropout rate of subjects toward the end of the study (18).
Monitoring weight changes for a longer duration in
adolescents is important because of the developmental
changes that accompany the onset of puberty. The
growth spurt during adolescence is associated with
weight and height velocities greater than between the
ages of 5 and I 0 years (25). This suggests that
susceptibility to hormonal contraception may be
selectively accentuated in early adolescence, which is
associated with the onset of menarche and the use of
hormonal contraception. Rather than causing a net
weight gain, hormonal contraception could accelerate
pubertal development, leading to the final body weight
set point that the same subject would have attained
eventually if not placed on hormonal contraception.
However, the short duration of studies in this field
precludes such a viable conclusion.
The provision of counseling may be an effective
intervention preventing weight gain. The present study
is quite unique because unlike other studies, the subjects
were provided with preventive counseling at the initial
visit and continuous counseling at each follow-up visit.
The counseling each subject received addressed a wide
variety of issues such as nutrition, dealing with the side
effects of contraception, ensuring compliance, and
addressing psychological issues related to the wellbeing cf the patient. In contrast, continuous counseling
was not reported in other studies investigating the
association between hormonal contraception and weight
gain (3-5, I 0,11, 13-16). Davies et al (26) recommended
that clinicians promote delayed sexual activity and
provide counseling to adolescents considering hormonal
contraception. The American Association of Pediatrics
also continues to recommend preventive, but not
continuous counseling to this adolescent population
regarding the use of contraceptives (2).
The initial weight before using hormonal contraception may be associated with the degree of weight
gain in adolescents. For example, overweight in childhood or excessive body mass increment during
pregnancy are risk factors of obesity in the later period
of life (27). By analogy, one could hypothesize that
overweight adolescents are more susceptible to weight
gain induced by hormonal contraception. Risser et aJ

(24) found that adolescent subjects who gained> 5% of
their baseline weight at 3 months were at high risk
(93%) of gaining even more weight by one year.
In conclusion, earlier studies on the association of
hormonal contraception and weight changes in
adolescents reported significant weight gain due to
contraceptives. Despite their validity, the duration of
such studies, 6-24 months, remains relatively short in
the context of adolescent development and thus the
study is limited in its interpretive ability. Furthermore,
although most srudies provided preventive counseling at
the initiation of hormonal contraception, none of offered
a continuation in psychological counseling services. Our
retrospective study is the first to address this question
beyond 24 months and to show that weight gain in
hormonal contraception users is not significantly
different from the control group for up to 72 months. In
addition, our study is unique in offering psychological
counseling to patients dming follow-up visits, which
suggests that psychological counseling may be an
effective clinical intervention preventing the weight gain
traditionally associated with hormonal contraception.
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